Early dual antiplatelet therapy shows superior efficacy in reducing stroke recurrence compared with aspirin monotherapy.
The FDA has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
HealthDay News — The Pooled Cohort Equations (PCE) cardiovascular risk score stratifies risk for multiple ocular diseases, according to a study published online Dec. 29 in Ophthalmology.
For patients at high cardiovascular risk with overweight/obesity, semaglutide is associated with reduced burden of total hospital admissions.
The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.
Post hoc trial findings support aprocitentan’s potential cardiovascular and kidney-protective effects in patients with chronic kidney disease (CKD) with resistant hypertension.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback